NovoRapid Aspartate ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
299嚢胞性線維症1

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-005019-28-GB
(EUCTR)
09/05/200519/04/2005Diabetes therapy to improve body mass index pulmoanry function in cystic fibrosis subjects with abnormal blood glucoseDiabetes therapy to improve body mass index pulmoanry function in cystic fibrosis subjects with abnormal blood glucose Cystic fibrosis related diabetes mellitusTrade Name: NovoRapid Aspartate
INN or Proposed INN: Novo Rapid
Trade Name: Rapeglinide
INN or Proposed INN: Rapeglinide
Papworth Hospital NHS Foundation TrustNULLNot Recruiting Female: yes
Male: yes
6 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesUnited Kingdom